For the quarter ending 2026-03-31, KROS made $367K in revenue. -$23,708K in net income. Net profit margin of -6459.95%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue | 367 | 385 | 14,262 | 18,168 |
| Research and development | 16,097 | 17,912 | 19,519 | 43,503 |
| General and administrative | 10,147 | 11,743 | 10,127 | 14,482 |
| Total operating expenses | 26,244 | 29,655 | 29,646 | 57,985 |
| Income (gain) from operations | -25,877 | -29,270 | -15,384 | -39,817 |
| Research and development incentive income | - | 0 | - | - |
| Dividend income | 2,335 | 4,022 | 6,933 | 7,120 |
| Other expense, net | -166 | 273 | -253 | -221 |
| Total other income, net | 2,169 | 4,295 | 6,680 | 6,899 |
| Income (gain) before income taxes | -23,708 | -24,975 | -8,704 | -32,918 |
| Income tax provision | 0 | -1,514 | -1,424 | -2,222 |
| Net income (gain) | -23,708 | -23,461 | -7,280 | -30,696 |
| Basic EPS | -1.21 | -0.866 | -0.18 | -0.76 |
| Diluted EPS | -1.21 | -0.804 | -0.18 | -0.76 |
| Basic Average Shares | 19,629,906 | 27,089,218 | 40,623,364 | 40,612,907 |
| Diluted Average Shares | 19,629,906 | 29,178,828 | 40,623,364 | 40,612,907 |
Keros Therapeutics, Inc. (KROS)
Keros Therapeutics, Inc. (KROS)